EGFR and interstitial lung disease: The study found that adverse reactions leading to ILD with EGFR-AKI occurred primarily in the adult population, with a particular concentration in the 65–85-year-old age group osimertinib (156 cases) and gefitinib (76 cases) were the most reported.